Alessandra Andreotti

Mrs. Alessandra Andreotti

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2025 in Journal of Medical Systems
Verified
Journal Article
Open access
PDF file
ABAntonio Balordi
Antonio Balordi
ABAlice Bernasconi
Alice Bernasconi
AAAlessandra Andreotti
Alessandra Andreotti
SGStefano Guzzinati
Stefano Guzzinati
Rafael CabañasRafael Cabañas
Rafael Cabañas
Alessio ZangaAlessio Zanga
Alessio Zanga
Cancer treatments might lead to several long-term effects. In this work we investigate their causal role on ischemic heart disease and their potential precursors (i.e. hypertension and dyslipidemia) of the ovarian suppression therapy in adolescent and young adult (AYA) breast cancer (BC) survivors. Additionally, we assess the external validity of our findings through comparative analysis of regional data. We take advantage of a causal network model that leverage on observational data on 1-year AYA BC survivors living the Lombardy region in Italy. Using a structural causal model (SCM) and counterfactual analysis within Pearl’s causal inference framework, we estimate the Average Causal Effect (ACE), Probability of Necessity (PN), and Probability of Sufficiency (PS) for the cause-effect relationships. Data of a regional cohort of AYA BC patients living in the Veneto region were used to externally validate results. Ovarian suppression was found to be a necessary but not sufficient cause for ischemic heart disease (PN > 97.8%; PS < 1.97%). While PN is high for both hypertension and dyslipidemia, PS varied suggesting ovarian suppression alone could induce hypertension in about 30% of cases but was rarely sufficient for dyslipidemia onset. External validation confirmed the robustness of findings across regions. Our experimental results may be of interest for clinicians who aim at personalizing the follow-up of AYA BC survivors, with particular attention to be paid in monitoring the hypertension onset or in its prevention. The study demonstrates the value of counterfactual reasoning and causal inference when working with real-world data.

14 February 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SGStefano Guzzinati
Stefano Guzzinati
AAAlessandra Andreotti
Alessandra Andreotti
TLTania Lopez
Tania Lopez
SGSilvia Gori
Silvia Gori
AGAlberto Gagliani
Alberto Gagliani
SFSilvia Francisci
Silvia Francisci
Objectives: The study aims to analyze care and cost patterns in the Veneto region for cancer patients in the final phase of their disease. Methods: The study cohort includes adult patients alive on 1.1.2018, which have been diagnosed with cancer at the age 15+ in a 28-years period, spanning from 1990 to 2017, and died within 12 months from prevalence date. The end-of-life (EOL) prevalent cases included in the study cohort are identified by the Veneto Tumor Registry. Primary tumors considered in the analysis are colon, rectum, skin melanoma, female breast, thyroid. Patient monthly average EOL costs, patient annual average EOL costs and total regional costs have been estimated separately for each cancer site/sex/age group/health care service database. Results: The estimated EOL total cost, for the five analyzed cancer types in the Veneto Region, is approximately 53 million euros. Costs associated with cancer treatment tend to increase in the final phase of the disease. In general, Hospital Admission is the main driver cost in all types of cancer considered, with the only exception in melanoma, where Hospital Drugs features the highest contribution. Moreover, costs differ significantly depending on the type of cancer, gender, and age, revealing highest average costs associated with younger patients. Conclusions: This study provides a comprehensive analysis of healthcare budget distribution in the last year of life, enabling healthcare planners to predict cancer burden in the future. This model can be applied to other Italian regions and countries with different healthcare systems.

21 April 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
EFEliana Ferroni
Eliana Ferroni
AAAlessandra Andreotti
Alessandra Andreotti
SGStefano Guzzinati
Stefano Guzzinati
SBSusanna Baracco
Susanna Baracco
MBMaddalena Baracco
Maddalena Baracco
MZManuel Zorzi
Manuel Zorzi
Background: Population-level evidence on delivery of neuro-oncology care is essential for evaluating access, equity, and quality of treatment pathways. However, real-world data describing how patients with central nervous system (CNS) tumors, especially with glioblastoma, are managed across healthcare systems remain limited. This study aimed to characterize treatment pathways using linked registry and administrative data within a regional care network. Methods: All adult CNS tumors diagnosed between 2016 and 2020 were identified in the Veneto Cancer Registry. Tumor grading was derived using a validated text-mining algorithm, and surgical, radiotherapy, and systemic treatments were captured through linkage with regional healthcare utilization databases. Patterns of care were evaluated by tumor subtype, grade, and diagnostic pathway. Results: Among 1634 histologically confirmed tumors, glioblastoma represented the largest group. Surgical intervention was widely implemented, with high resection rates in glioblastoma and meningioma. Combined chemoradiotherapy constituted the primary adjuvant approach for glioblastoma and high-grade diffuse gliomas, whereas management of lower-grade tumors showed greater variability. Approximately one-third of patients received no oncologic therapy, primarily associated with older age or diagnostic uncertainty. Analysis of recurrent glioblastoma showed heterogeneous systemic treatment use, reflecting evolving therapeutic practice. Conclusions: Linking population-based registry and administrative data provides actionable insight into real-world delivery of neuro-oncology care, in particular for glioblastoma patients. This approach enables monitoring of treatment variability, identification of potential access gaps, and evaluation of system-level performance, supporting data-driven planning of multidisciplinary services and future quality improvement initiatives.

16 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
EFEliana Ferroni
Eliana Ferroni
AAAlessandra Andreotti
Alessandra Andreotti
SGStefano Guzzinati
Stefano Guzzinati
SBSusanna Baracco
Susanna Baracco
MBMaddalena Baracco
Maddalena Baracco
MZManuel Zorzi
Manuel Zorzi
Background: Population-level evidence on delivery of neuro-oncology care is essential for evaluating access, equity, and quality of treatment pathways. However, real-world data describing how patients with central nervous system (CNS) tumors, especially with glioblastoma, are managed across healthcare systems remain limited. This study aimed to characterize treatment pathways using linked registry and administrative data within a regional care network. Methods: All adult CNS tumors diagnosed between 2016 and 2020 were identified in the Veneto Cancer Registry. Tumor grading was derived using a validated text-mining algorithm, and surgical, radiotherapy, and systemic treatments were captured through linkage with regional healthcare utilization databases. Patterns of care were evaluated by tumor subtype, grade, and diagnostic pathway. Results: Among 1,634 histologically confirmed tumors, glioblastoma represented the largest group. Surgical intervention was widely implemented, with high resection rates in glioblastoma and meningioma. Combined chemoradiotherapy constituted the primary adjuvant approach for glioblastoma and high-grade diffuse gliomas, whereas management of lower-grade tumors showed greater variability. Approximately one third of patients received no oncologic therapy, primarily associated with older age or diagnostic uncertainty. Analysis of recurrent glioblastoma showed heterogeneous systemic treatment use, reflecting evolving therapeutic practice. Conclusions: Linking population-based registry and administrative data provides actionable insight into real-world delivery of neuro-oncology care, in particular for glioblastoma patients. This approach enables monitoring of treatment variability, identification of potential access gaps, and evaluation of system-level performance, supporting data-driven planning of multidisciplinary services and future quality improvement initiatives.